Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Sean Janzen who wrote (1372)	1/16/2000 9:27:00 PM
From: David Culver	Read Replies (2) \| Respond to of 1501

Has anyone looked lately at the market cap of IZP compared to competitors. I remember seeing a comparision like this a few years ago. I think one company was Arris which was developing an somewhat similar drug. dave

To: Sean Janzen who wrote (1372)	1/17/2000 10:10:00 AM
From: Charles Salski	Read Replies (1) \| Respond to of 1501

Hi Sean, << If the IPO market is hot for biotechs then lets do it.>> Whole heartily agree with you and I believe so does IAN MCBEATH. Some examples that stand out in the interview. <<Outside of accelerating the development of our technology, two key objectives in 2000 are to achieve another collaborative partnership with a major pharmaceutical company, and to be proactive in accessing growth opportunities through strategic M&A activities.>> <<We intend to seek out any opportunities to accelerate the time to market of our products,such as using strategic partnering and being proactive in areas such as mergers and acquisitions.>> <<TWST: Could you tell us about Inflazyme's competitive advantages? What sets the company apart from your competition? Mr. McBeath: I think you can sum our advantage up in three words, products, people and finance. We've got a broad technology base in comparison to many companies at the same stage of development. We're developing three separate and distinct novel product platforms, all targeted to inflammatory disease. These three product platforms are all based on very different chemical scaffolds and at this time we can see at least nine products that potentially can come out of these. This therefore means that the impact on the Company of failure of any one compound is reduced. Our scientific expertise is well established, particularly in the areas of identification of novel chemical structures from nature, medicinal and synthetic chemistry, and our understanding of inflammatory disease biology. We believe that this allows us to create novel therapeutic products with advantages over currently marketed products. As I mentioned before, our management team and Board are especially strong for a company such as ours. The breadth of experience from both biotechnology and big pharmaceutical companies, as well as Wall Street on our board, gives us a lot of advantages in planning and setting our strategic objectives. Financially we've currently got a strong balance sheet. Against our current R&D plans, we've got approximately almost three years worth of cash available. This gives us flexibility in decision making, and a buffer, should we have any unexpected challenges in one of our product development programs. It also puts us in a good position if we want to consider any potential M&A activities.>> For those who missed this interview. twst.com I expect to see some major changes for this company this year. The company has the product and management to make it happen. Charles